BRENTUXİMAB-ESHAP PROTOKOLÜ

Kaynaklar:

1-NCCP SACT clinical Advisory lymphoid group: Brentuximab vedotin in combination with chemotherapy in patients with relapsed or primary refractory Hodgkin lymphoma. Evidence into practice –rapid review June 2018

2- Garcia-Sanz, R et al. Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO) Blood 2016 128:1109

3-Garcia-Sanz, R et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group) Annals of Oncology 30: 612–620, 20

4-Labrador J. Cabrero-Calvo M. Perez-Lopez E. et al. ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma. Ann Hematol. 2014; 93: 1745-1753.

5-Martinez C. Diaz-Lopez A. Rodriguez-Calvillo M. et al. Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy. Br J Haematol. 2016; 174: 859-867

6-Moskowitz C.H. Nimer S.D. Zelenetz A.D. et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001; 97: 616-623

7-Aparicio J. Segura A. Garcera S. et al. ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol. 1999; 10: 593-595.

8-Okeley N.M. Miyamoto J.B. Zhang X. et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010; 16: 888-897

9- Younes A. Gopal A.K. Smith S.E. et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012; 30: 2183-2189

10-Moskowitz C.H. Nademanee A. Masszi T. et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 385: 1853-1862.

12-Moskowitz A.J. Schoder H. Yahalom J. et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015; 16: 284-292.